Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Chronic Spontaneous Urticaria
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Article

April 1, 2004

Oral tazarotene delivers lasting results for plaque psoriasis

Washington - According to a poster study presented at the annual American Academy of Dermatology meeting, oral tazarotene (Tazorac; Allergan Inc., Irvine, Calif.) gives patients with plaque psoriasis significant improvements that continue after treatment stops. The blinded, placebo-controlled multicenter study of approximately 700 patients shows that oral tazarotene delivers several advantages over existing alternatives for treating plaque psoriasis.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!